COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD K458R mutant (SRBD K458R,C-HisTag)
Cat No.: GMP-V-2019nCoV-Smu-012
Order information
| Package | Catalog No. | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| 1mg | GMP-V-2019nCoV-Smu-012-1mg | 5990 | ||
| 10mg | GMP-V-2019nCoV-Smu-012-10mg | 38790 | ||
| 100mg | GMP-V-2019nCoV-Smu-012-100mg | 258000 | ||
| ≥100mg | GMP-V-2019nCoV-Smu-012-xmg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Accession Number | QHD43415.1 |
| Expression platform | 2019-nCoV(SARS-CoV-2, SARS2-coronavirus) |
| Isotypes | Mamamlian (human cell) |
| Tag | C-His |
| Products description | Recombinant 2019-nCoV(SARS-CoV-2) receptor binding domain (RBD) from the Spike Protein (S protein) with K458R mutation was expressed in mammanlian cell (human cells) expression system. The target gene encoding Arg319-Phe541(K458R) was expressed with 6 HIS tag at the C-terminus. |
| Bioactivity validation | ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays; |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay. |
| predicted Molecular Mass | 26kDa |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2)
Spike Protein RBD K458R mutant (SRBD K458R,C-HisTag)
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19vaccines and therapeutic antibodies.
<

